english.prescrire.org > Spotlight > Archives : 2022 > Bivalent mRNA covid-19 vaccines that also target the Omicron variant: more antibodies

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2022 : 1 | 30 | 60

Bivalent mRNA covid-19 vaccines that also target the Omicron variant: more antibodies

 Marketing Authorisations  Four bivalent messenger RNA (mRNA) vaccines, based on the first Sars-CoV-2 strain isolated and a strain of the Omicron variant of this virus, have been authorised in the European Union. How do Prescrire's editors rate these vaccines?
Full article (2 pages) available for download by subscribers.

  • The four vaccines, each containing a different second component targeting an Omicron subvariant, are: tozinameran + riltozinameran (Comirnaty Original/Omicron BA.1°) and tozinameran + famtozinameran (Comirnaty Original/Omicron BA.4-5°), marketed by BioNTech and Pfizer; and elasomeran + imelasomeran (Spikevax bivalent Original/Omicron BA.1°) and elasomeran + davesomeran (Spikevax bivalent Original/Omicron BA.4-5°) from Moderna.
     
  • Two immunogenicity trials were conducted with bivalent BA.1 vaccines, and their results were extrapolated to the bivalent BA.4-5 vaccines, which have the same composition apart from the Omicron variant-derived mRNA fragment they contain. 
     

©Prescrire 1 December 2022

Source: "Bivalent mRNA covid-19 vaccines that also target the Omicron variant: more antibodies" Prescrire International 2022; 31 (243). Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >